The storefronts themselves "do not maintain any inventory, pharmacy licensure, or clinical infrastructure", so the product has to already exist, "manufactured, labeled, and ready for distribution by the OpenLoop-Triad network." Thus, the plaintiff is showing (fairly convincingly) that the "back-end infrastructure provider," the prescribing entity, and the pharmacy are all in the same family, selling a business-in-a-box with oral tirzepatide ready on formulary to anyone who wants to be a telehealth brand
Women who are not planning to become pregnant might want to use backup barrier methods or switch to non-oral contraceptive options, such as patches, rings, or IUDs, particularly during the first few weeks after a dose increase
PMID: 41916313 Br J Pharmacol Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury
1521, www.ncbi.nlm.nih.gov/pmc/articles/PMC5808366/, Weschawalit, Sinee, et al
Sethi S, Barjaktarevic IZ, Tashkin DP